LAWRENCEVILLE, NJ
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS OUTCOMES RESEARCH, founded in 1995, is a mid-sized nonprofit in the Medical Research sector that reported $19.7M in total revenue in fiscal year 2024.
THE MISSION OF INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS OUTCOMES RESEARCH (ISPOR) IS TO PROMOTE HEALTH ECONOMICS AND OUTCOMES RESEARCH EXCELLENCE TO IMPROVE DECISION MAKING FOR HEALTH GLOBALLY.
ISPOR IS A GLOBAL, NONPROFIT SCIENTIFIC AND EDUCATIONAL SOCIETY ADVANCING EXCELLENCE IN HEALTH ECONOMICS AND OUTCOMES RESEARCH (HEOR) TO IMPROVE HEALTHCARE DECISION-MAKING WORLDWIDE.ISPOR HAS OVER...
ISPOR IS A GLOBAL, NONPROFIT SCIENTIFIC AND EDUCATIONAL SOCIETY ADVANCING EXCELLENCE IN HEALTH ECONOMICS AND OUTCOMES RESEARCH (HEOR) TO IMPROVE HEALTHCARE DECISION-MAKING WORLDWIDE.ISPOR HAS OVER 18,000 INVIDIVIDUAL AND CHAPTER MEMBERS ACROSS MORE THAN 100 COUNTRIES WHO ARE INVOLVED IN HEALTHCARE ECONOMICS AND OUTCOMES RESEARCH, INCLUDING STAKEHOLDERS FROM ACADEMIA, GOVERNMENT, PAYERS, INDUSTRY, HEALTHCARE PROVIDERS, AND PATIENT ORGANIZATIONS.ISPOR FOSTERS THE USE OF HEALTH ECONOMICS AND OUTCOMES RESEARCH FOR HEALTHCARE POLICY AND DECISION-MAKING WORLDWIDE WITH OVER 75 REGIONAL CHAPTERS AND NEARLY 100 STUDENT NETWORKS ACROSS THE GLOBE. THROUGH TASK FORCES, COUNCILS, AND SPECIAL INTEREST GROUPS, ISPOR ALSO DEVELOPS CONSENSUS GUIDELINES ON OUTCOMES RESEARCH METHODS AND THE APPLICATION OF THIS RESEARCH IN HEALTHCARE DECISIONS. THE ISPOR GOOD PRACTICES REPORTS ARE HIGHLY CITED, EXPERT CONSENSUS GUIDANCE RECOMMENDATIONS THAT SET INTERNATIONAL STANDARDS FOR HEOR AND ITS USE IN HEALTHCARE DECISION MAKING. OTHER ISPOR REPORTS AND RESEARCH TOOLS PROVIDE GUIDANCE ON IMPORTANT AREAS SUCH AS HTA, HEALTH POLICY, AI AND REAL-WORLD EVIDENCE. THESE RESOURCES ARE WIDELY USED WITH OVER 1,000,000 DOWNLOADS ANNUALLY.ISPOR PUBLISHES THREE SCIENTIFIC JOURNALS AND MULTIPLE NEWSLETTERS TO ADVANCE THE FIELD OF HEALTH ECONOMICS AND OUTCOMES RESEARCH AND HELP HEALTHCARE LEADERS MAKE EVIDENCE-BASED DECISIONS. IN 2024, THE SOCIETY PUBLISHED 5 NEW ISPOR REPORTS IN ITS JOURNAL VALUE IN HEALTH AND PROVIDED EDUCATIONAL EXCELLENCE THROUGH INITIATIVES LIKE THE HEOR LEARNING LAB, SHORT COURSES, AND WEBINARS.ISPOR'S ANNUAL CONFERENCES AND SUMMITS PROVIDE A FORUM TO FACILITATE THE INTERCHANGE OF SCIENTIFIC KNOWLEDGE IN HEALTH ECONOMICS AND OUTCOMES RESEARCH AND ITS USE IN HEALTHCARE POLICY AND DECISION-MAKING. IN 2024, ISPOR HOSTED INTERNATIONAL CONFERENCES IN ATLANTA AND BARCELONA WITH A RECORD ATTENDANCE OVER 10,000 ATTENDEES.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $19,723,828 | $18,483,761 | +0.1% |
| Expenses | $19,363,160 | $17,227,897 | +0.1% |
| Net Income | $360,668 | $1,255,864 | -0.7% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| EBERECHUKWU ONUKWUGHA MS PHD | PRESIDENT (SINCE JUNE 2024) | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| UWE SIEBERT MD MP SCD | PRESIDENT-ELECT | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| BRIAN O'ROURKE | PAST PRESIDENT (SINCE JUNE 2024) | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| SEAN SULLIVAN MSC PHD | TREASURER | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| AMY K O'SULLIVAN PHD | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| RAMIRO GILARDINO MD MHS | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| DALIA DAWOUD PHD | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| DANIEL OLLENDORF PHD | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| ELISABETH FENWICK PHD MSC | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| KATJA RUDELL PHD MSC | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| LUCINDA ORSINI DPM MPH | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| BETH DEVINE PHD | DIRECTOR (UNTIL 06/24) | 2.00 |
Director
|
$0 | $0 | $0 |
| MARLENE GYLDMARK MPHIL | DIRECTOR (UNTIL 06/24) | 2.00 |
Director
|
$0 | $0 | $0 |
| ANDREA MANCA MSC PHD | DIRECTOR (UNTIL 06/24) | 2.00 |
Director
|
$0 | $0 | $0 |
| DONG-CHURL SUH PHD | DIRECTOR (UNTIL 06/24) | 2.00 |
Director
|
$0 | $0 | $0 |
| JAN ELIAS HANSEN PHD | PAST PRESIDENT (UNTIL JUNE 2024) | 2.00 |
Officer
Director
|
$0 | $0 | $0 |
| SUSAN CAPON | CHIEF OPERATING OFFICER | 40.00 |
Officer
|
$317,919 | $28,231 | $346,150 |
| ELIZABETH LANE | CHIEF MARKETING OFFICER | 40.00 |
Highest
|
$233,634 | $31,859 | $265,493 |
| LAURA PIZZI | CHIEF SCIENCE OFFICER | 40.00 |
Highest
|
$318,549 | $12,273 | $330,822 |
| CHANTAL ALMONORD | CHIEF INFO & ENGAGEMENT OFFICER | 40.00 |
Highest
|
$201,641 | $34,293 | $235,934 |
| SEAN GORMLEY | DIRECTOR, BUSINESS DEVELOPMENT | 40.00 |
Highest
|
$222,811 | $36,692 | $259,503 |
| PAUL WONG | DIRECTOR, GLOBAL EVENTS | 40.00 |
Highest
|
$204,550 | $21,913 | $226,463 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | $19,723,828 | $19,363,160 | $30,224,428 | $360,668 |
| 2023 | $18,483,761 | $17,227,897 | $27,237,931 | $1,255,864 |
| 2022 | $14,593,000 | $15,156,974 | $23,939,884 | $-563,974 |
| 2021 | $8,054,618 | $9,567,254 | $24,515,564 | $-1,512,636 |
| 2020 | $14,162,413 | $9,413,154 | $26,278,189 | $4,749,259 |
| 2019 | $16,559,826 | $15,114,605 | $20,352,941 | $1,445,221 |
| 2018 | $16,282,259 | $14,773,834 | $17,365,453 | $1,508,425 |
Compare INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS OUTCOMES RESEARCH with other nonprofits in New Jersey and across the country.